Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential PIPAC with immunosuppressive agents and tocilizumab for peritoneal metastatic adenocarcinoma
ChiCTR2600123267Phase 2Not yet recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of tocilizumab in peritoneal carcinomatosis (PC) (2 arms), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: Safety observation during the trial. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
tocilizumab
03
Conditions
peritoneal carcinomatosis (PC)
Beyond the preview
Go deeper on ChiCTR2600123267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123267.